Dr. Bacharier's career has focused on clinical research to help understand and improve the care of children with asthma. His clinical/translational research efforts are directed at the pathogenesis of asthma in early life and approaches to asthma management throughout childhood, including multi-center federally funded clinical trials in asthma. He is the Principal investigator on several NIH-sponsored clinical and translational studies, including the Respiratory Syncytial Virus (RSV) Bronchiolitis in Early Life (RBEL) prospective cohort study (R01 HL092486-01A2). Dr. Bacharier served as the Principal Investigator of the St. Louis site of the NHBLI-funded AsthmaNet (U10HL098098), a multi-centered network exploring new approaches to asthma therapy in children and adults, as well as mechanistic studies exploring the pathobiology which underlies asthma. He served as the lead investigator for the first 2 AsthmaNet clinical trials in the pediatric age group. He currently serves as a Co-Investigator in the NHLBI-PrecISE Network [UG1HL139119] and as Principal Investigator for the Clinical Coordinating Center for the NHLBI-supported Vitamin D Antenatal Asthma Reduction Trial (R01 HL091075) examining the effects of antenatal vitamin D supplementation on early life respiratory disease and asthma. Dr. Bacharier serves as a site co-principal investigator in the NIAID-supported Inner City Asthma Consortium [ICAC, NO1 AI025496], and including the URECA birth cohort study, CRITICAL and MUPPITS studies. He is the St. Louis site Co-PI for the ORBEX [R01 HL30045] multicenter asthma prevention trial.

For Google Scholar listing, click here.

For complete reference list, click here.

>> View Publications In PubMed

Abnormalities of cardiac rhythm are a common and serious public health problem. However, the therapies used to treat arrhythmias are often ineffective, and can sometimes even exacerbate arrhythmias. Research in this laboratory is directed at elucidating mechanisms underlying abnormalities of cardiac rhythm and mechanisms underlying variable responses to antiarrhythmic drug treatments. Since antiarrhythmic drugs affect the function of cardiac ion channels, it is one working hypothesis in the laboratory that variable responses to drug therapy may reflect variable function or expression of genes encoding ion channels or proteins involved in drug disposition. Thus, a major focus of work in the laboratory is elucidation of factor(s) that determine ion channel gene expression in cardiac tissue. Approaches include identification of new genes, identification of DNA polymorphisms and characterization of their functional effects on disease and drug responses, and modulation of expression in cultured heart cells (e.g. by antisense) and gene knockout in mice.

>> View Publications In PubMed

Dr. Plancarte is interested in improving the healthcare of hospitalized children through high-quality research in perioperative medicine as well as research addressing health disparities.

Dr. Patterson conducts translational research evaluating host-microbiome interactions during critical illness. She is investigating the gastrointestinal microbiome in patients with congenital heart disease and critical illness to establish ways microbiome changes impact patient nutritional and infectious disease outcomes. Her multidisciplinary team is working to establish a microbiome biorepository which will be foundational in the study of microbiome and metabolomic alterations during specific disease states and discovering treatments to optimize the gastrointestinal microbiome and improve patient outcomes.

Dr. Hipp is interested in the rigorous application of quality improvement and implementation science methodologies to improve the care of critically ill children with heart disease, particularly focused on sedation, delirium, and early mobilization.

>> View Publications on PubMed